期刊文献+

不同基因突变的原发性血小板增多症患者的临床特征 被引量:1

Clinical features of essential thrombocythemia with different gene mutations
下载PDF
导出
摘要 目的观察不同原发性血小板增多症(ET)基因突变患者的临床特征及其实验室检查结果的变化。方法选择北京市海淀医院血液内科2015年7月至2020年6月收治的56例初诊ET患者。根据基因突变结果将患者分为JAK2突变组(n=40)、CALR突变组(n=6)和基因阴性组(n=10)。比较三组患者的临床特征(性别、年龄、临床症状、血栓及栓塞事件等)和实验室检查指标[血小板数(PLT)、白细胞数(WBC)、血红蛋白(Hb)、纤维蛋白原(FIB)、血栓弹力图(TEG)、基因突变、乳酸脱氢酶(LDH)、血钾、血糖(GLU)]的差异。结果JAK2突变组患者的平均发病年龄明显高于CALR突变组和基因阴性组,差异均有统计学意义(P<0.05),而三组患者的性别、脾脏是否肿大、TEG是否异常、是否发生血栓及栓塞事件比较差异均无统计学意义(P>0.05);CALR突变组患者WBC数、Hb水平明显低于JAK2突变组、基因阴性组,LDH水平则明显高于JAK2突变组、基因阴性组,而基因阴性组患者的GLU水平明显高于JAK2突变组、CALR突变组,差异均有统计学意义(P<0.05);三组患者的Plt数、FIB水平比较差异均无统计学意义(P>0.05)。结论JAK2基因突变的ET患者发病率高,年龄大,而CALR突变及CALR阴性患者WBC和Hb水平较低,故ET患者多样化的基因突变类型具有不同的临床特征。 Objective To observe the clinical features and changes in laboratory examination results in patients with essential thrombocythemia(ET)with different gene mutations.Methods Fifty-six patients with newly diagnosed ET admitted to the Department of Hematology,Beijing Haidian Hospital from July 2015 to June 2020 were selected.The patients were divided into JAK2 mutation group(n=40),CALR mutation group(n=6),and gene negative group(n=10)according to the gene mutation results.The differences in clinical characteristics(gender,age,clinical symptoms,thrombotic and embolic events),and laboratory examination indexes[platelet count(PLT),white blood cell count(WBC),hemoglobin(Hb),fibrinogen(FIB),thromboelastography(TEG),gene mutation,lactate dehydrogenase(LDH),blood potassium,and blood glucose(GLU)]were compared among the three groups.Results The average age of onset in JAK2 mutation group was significantly higher than that in CALR mutation group and gene negative group,and the differences were statistically significant(P<0.05).However,there were no significant differences in age,whether the spleen was or not,whether TEG was abnormal or not,and whether there were thrombosis and embolic events among the three groups(P>0.05).The number of WBC and Hb level in patients with CALR mutation group were significantly lower than those in JAK2 mutation group and gene negative group,while the level of LDH was significantly higher than those in JAK2 mutation group and gene negative group,while the level of GLU in patients with gene negative group was significantly higher than those in JAK2 mutation group and CALR mutation group(P<0.05).There was no significant difference in Plt number and FIB level among the three groups(P>0.05).Conclusion ET patients with JAK2 mutation have a high incidence and old age,while patients with CALR mutation and CALR negative have low WBC and Hb levels.Therefore,the diversed of gene mutations in ET patients have different clinical characteristics.
作者 宁军 龚浩 任晓磊 丁超 王晨龙 张敏 刘彦 NING Jun;GONG Hao;REN Xiao-lei;DING Chao;WANG Chen-long;ZHANG Min;LIU Yan(Department of Oncology and Hematology,Beijing Haidian Hospital,Beijing 100080,CHINA;Department of Hematology,Peking University Third Hospital,Beijing 100191,CHINA)
出处 《海南医学》 CAS 2022年第10期1302-1304,共3页 Hainan Medical Journal
关键词 原发性血小板增多症 基因突变 Janus激酶2突变 钙网蛋白突变 基因阴性 临床特征 Essential thrombocythemia(ET) Gene mutation Janus kinase 2 mutation Calreticulin mutation Gene negative Clinical characteristics
  • 相关文献

参考文献11

二级参考文献70

  • 1Fantasia F, Di Capua EN, Cenfra N ,et al. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F ex- pression levels and control genes in Ph-negative myeloproliferative neo- plasms [ J ] Ann Hematol,2013,93 (4) :609-616.
  • 2Tefferi A, Vainchenker W. myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strat- egies[J]. J Clin Oncol,2011,29(5) :573-582.
  • 3Boissinot M, Cleyrat C, Vilaine M, et al. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-I 1 are over-expressed in Pol- ycythemia vera and contribute to the growth of clonal crythoblasts in- dependently of JAK2 V617 F [ J ]. Oncogene, 2011,30 ( 8 ) :990 -1001.
  • 4Kerguel6n Fuentes AE, HernOndez-Maraver D, Lombardia L, et al. Clinical significance of the quantification of JAK2V617F allele bur- den in classical Ph-negative myeloproliferative neoplasma [ J ] Med Cfin(Barc) ,2012,139(9) :373-378.
  • 5Harrison CN, Bareford D, Butt N, et al. Guideline for investiga- tion and management of adults and children presenting with a thrombocytosis [J]. Br J Haematol, 2010, 149 (3):352-375. doi: 10.1111/j.1365-2141.2010.08122.x.
  • 6Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet [J]. J Clin Oncol, 2011, 29 (6):761-770. doi: 10.1200/ JCO.2010.31.8436.
  • 7Harrison CN, Butt N, Campbell P, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia [J]. Br J Haematol, 2014, 167 (3): 421-423. doi: 10.1111/bjh.12986.
  • 8Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2015, 26 Suppl 5:v85-99. doi: 10.1093/annonc/mdv203.
  • 9Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127 (20):2391-2405. doi: 10.1182/blood-2016-03-643544.
  • 10Besses C, Hemfindez-Boluda JC, Prez Encinas M, et al. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method[J]. Ann Hematol, 2016, 95 (5):719-732. doi: 10.1007/ s00277-016-2614-1.

共引文献100

同被引文献9

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部